Onyx Biotec MD, chairman, board of directors and AGM
NSE: ONYXPharmaceuticals & Biotechnology
Share price at the NSE close on 23 Oct 2026. Previous close ₹37.00.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹67 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 14 May 2026
- 1.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 14 May 2026
- −0.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 14 May 2026
- 0.27
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 4,000100.0% delivered
Onyx Biotec board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- R C A AND CO LLPPeer-review certificate valid to Jan 2027
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Onyx Biotec AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Onyx Biotec share news and announcements
Annual general meeting, 28 Sep 2026
646 shareholders on the register on 21 Sep 2026; present: 3 promoters and 7 others; votes counted by Md Shahnawaz / M SHAHNAWAZ & ASSOCIATES.The company's voting result (opens in a new tab)
- To consider and adopt the: Audited Annual Financial Statements of the Company for the financial year ended 31st March, 2026 and the Reports of the Board of Directors and the Auditors’ thereon; andOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 70.75% · promoters 99.73% · institutions 0.00% · other public 52.36%
- To appoint a Director in place of Mr. Harsh Mahajan (DIN: 09793917), who retires by rotation and being eligible offers himself for re-appointment.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 70.75% · promoters 99.73% · institutions 0.00% · other public 52.36%
- Ratification of remuneration to Cost Auditors of the Company.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 70.75% · promoters 99.73% · institutions 0.00% · other public 52.36%
- Change in designation of Mr. Naresh Kumar (DIN: 02214241) from Whole-Time Director to Managing Director of the Company.Special100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 70.75% · promoters 99.73% · institutions 0.00% · other public 52.36%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Mar 2026.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| Public IssuesNov 2024 | 25.38 | Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use | 6.08 | 4.34 | No |
| Public IssuesNov 2024 | 25.38 | Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections | 1.24 | 0.92 | No |
| Public IssuesNov 2024 | 25.38 | Prepayment or repayment of all or a portion of certain loans availed by our Company | 12.00 | 12.00 | No |
| Public IssuesNov 2024 | 25.38 | General corporate purposes | 6.06 | 5.99 | No |